1. Home
  2. VSTS vs MPLT Comparison

VSTS vs MPLT Comparison

Compare VSTS & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vestis Corporation

VSTS

Vestis Corporation

HOLD

Current Price

$12.88

Market Cap

1.6B

Sector

N/A

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$29.69

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VSTS
MPLT
Founded
1936
2018
Country
United States
United States
Employees
N/A
133
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
VSTS
MPLT
Price
$12.88
$29.69
Analyst Decision
Sell
Strong Buy
Analyst Count
4
7
Target Price
$5.88
$32.67
AVG Volume (30 Days)
2.0M
239.8K
Earning Date
05-12-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,734,839,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.98
$12.24
52 Week High
$12.93
$33.28

Technical Indicators

Market Signals
Indicator
VSTS
MPLT
Relative Strength Index (RSI) 70.40 54.99
Support Level $6.81 $26.20
Resistance Level N/A $32.23
Average True Range (ATR) 0.72 1.99
MACD 0.07 -0.10
Stochastic Oscillator 95.80 73.08

Price Performance

Historical Comparison
VSTS
MPLT

About VSTS Vestis Corporation

Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: